StreetInsider.com News Articles

QIAGEN releases digital PCR assays for Bundibugyo ebolavirus research

Thu, 28 May 2026 16:06:41 -0400

QIAGEN N.V. (NYSE: QGEN) announced the availability of two custom-designed research-use-only digital PCR assays to support infectious disease research and surveillance efforts related to the Bundibugyo ebolavirus outbreak.

The assays are designed for use with the QIAcuity digital PCR system and target the nucleoprotein and VP35 regions of the virus. The company developed them using publicly available genomic sequence information released during the outbreak response.

Initial sequence analysis showed no mismatches against currently published outbreak sequences reviewed by QIAGEN. The assays are intended for qualified laboratories to evaluate emerging pathogen targets in research, wastewater surveillance and environmental monitoring settings.

The company stated the

QIAGEN releases digital PCR assays for Bundibugyo ebolavirus research

Thu, 28 May 2026 16:06:41 -0400

The company stated the

QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak

Thu, 28 May 2026 16:05:00 -0400

Two custom-designed research-use-only (RUO) QIAcuity digital PCR assays now available to target Bundibugyo ebolavirus sequences associated with the current outbreak

Assays designed for integration into existing QIAcuity to support research, wastewater surveillance and analytical evaluation by qualified laboratories

QIAGEN’s broader Sample to Insight portfolio includes kits for sample preparation and next-generation sequencing to support outbreak research workflows

VENLO, Netherlands, & GERMANTOWN, Md.--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the availability of two custom-designed research-use-only (RUO) digital PCR assays to support infectious disease research and surveillance efforts related to the Bundibugyo ebolavirus outbreak.

The

QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak

Thu, 28 May 2026 16:05:00 -0400

Two custom-designed research-use-only (RUO) QIAcuity digital PCR assays now available to target Bundibugyo ebolavirus sequences associated with the current outbreak

Assays designed for integration into existing QIAcuity to support research, wastewater surveillance and analytical evaluation by qualified laboratories

QIAGEN’s broader Sample to Insight portfolio includes kits for sample preparation and next-generation sequencing to support outbreak research workflows

The

QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak

Thu, 28 May 2026 16:05:00 -0400

Two custom-designed research-use-only (RUO) QIAcuity digital PCR assays now available to target Bundibugyo ebolavirus sequences associated with the current outbreak

Assays designed for integration into existing QIAcuity to support research, wastewater surveillance and analytical evaluation by qualified laboratories

QIAGEN’s broader Sample to Insight portfolio includes kits for sample preparation and next-generation sequencing to support outbreak research workflows

The

QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak

Thu, 28 May 2026 16:05:00 -0400

Two custom-designed research-use-only (RUO) QIAcuity digital PCR assays now available to target Bundibugyo ebolavirus sequences associated with the current outbreak

Assays designed for integration into existing QIAcuity to support research, wastewater surveillance and analytical evaluation by qualified laboratories

QIAGEN’s broader Sample to Insight portfolio includes kits for sample preparation and next-generation sequencing to support outbreak research workflows

The

QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak

Thu, 28 May 2026 16:05:00 -0400

Two custom-designed research-use-only (RUO) QIAcuity digital PCR assays now available to target Bundibugyo ebolavirus sequences associated with the current outbreak

Assays designed for integration into existing QIAcuity to support research, wastewater surveillance and analytical evaluation by qualified laboratories

QIAGEN’s broader Sample to Insight portfolio includes kits for sample preparation and next-generation sequencing to support outbreak research workflows

The

QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak

Thu, 28 May 2026 16:05:00 -0400

Two custom-designed research-use-only (RUO) QIAcuity digital PCR assays now available to target Bundibugyo ebolavirus sequences associated with the current outbreak

Assays designed for integration into existing QIAcuity to support research, wastewater surveillance and analytical evaluation by qualified laboratories

QIAGEN’s broader Sample to Insight portfolio includes kits for sample preparation and next-generation sequencing to support outbreak research workflows

The

QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak

Thu, 28 May 2026 16:05:00 -0400

Two custom-designed research-use-only (RUO) QIAcuity digital PCR assays now available to target Bundibugyo ebolavirus sequences associated with the current outbreak

Assays designed for integration into existing QIAcuity to support research, wastewater surveillance and analytical evaluation by qualified laboratories

QIAGEN’s broader Sample to Insight portfolio includes kits for sample preparation and next-generation sequencing to support outbreak research workflows

The

QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak

Thu, 28 May 2026 16:05:00 -0400

Two custom-designed research-use-only (RUO) QIAcuity digital PCR assays now available to target Bundibugyo ebolavirus sequences associated with the current outbreak

Assays designed for integration into existing QIAcuity to support research, wastewater surveillance and analytical evaluation by qualified laboratories

QIAGEN’s broader Sample to Insight portfolio includes kits for sample preparation and next-generation sequencing to support outbreak research workflows

The

QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak

Thu, 28 May 2026 16:05:00 -0400

Two custom-designed research-use-only (RUO) QIAcuity digital PCR assays now available to target Bundibugyo ebolavirus sequences associated with the current outbreak

Assays designed for integration into existing QIAcuity to support research, wastewater surveillance and analytical evaluation by qualified laboratories

QIAGEN’s broader Sample to Insight portfolio includes kits for sample preparation and next-generation sequencing to support outbreak research workflows

The

QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak

Thu, 28 May 2026 16:05:00 -0400

Two custom-designed research-use-only (RUO) QIAcuity digital PCR assays now available to target Bundibugyo ebolavirus sequences associated with the current outbreak

Assays designed for integration into existing QIAcuity to support research, wastewater surveillance and analytical evaluation by qualified laboratories

QIAGEN’s broader Sample to Insight portfolio includes kits for sample preparation and next-generation sequencing to support outbreak research workflows

The

QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows

Wed, 20 May 2026 16:05:00 -0400

New AI-powered scientific platform available on www.qiagen.com connects experiment planning, product discovery and workflow support through a single conversational interface

Natural-language experience helps reduce time spent searching across systems and connects customers more quickly to relevant QIAGEN information

Expands QIAGEN’s digital ecosystem with AI-driven workflow support embedded directly into the customer experience

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the global launch of QIA Agent, an AI-powered digital assistant designed to simplify how researchers plan experiments, identify suitable products, access technical information and manage

QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows

Wed, 20 May 2026 16:05:00 -0400

New AI-powered scientific platform available on www.qiagen.com connects experiment planning, product discovery and workflow support through a single conversational interface

Natural-language experience helps reduce time spent searching across systems and connects customers more quickly to relevant QIAGEN information

Expands QIAGEN’s digital ecosystem with AI-driven workflow support embedded directly into the customer experience

QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows

Wed, 20 May 2026 16:05:00 -0400

New AI-powered scientific platform available on www.qiagen.com connects experiment planning, product discovery and workflow support through a single conversational interface

Natural-language experience helps reduce time spent searching across systems and connects customers more quickly to relevant QIAGEN information

Expands QIAGEN’s digital ecosystem with AI-driven workflow support embedded directly into the customer experience

QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows

Wed, 20 May 2026 16:05:00 -0400

New AI-powered scientific platform available on www.qiagen.com connects experiment planning, product discovery and workflow support through a single conversational interface

Natural-language experience helps reduce time spent searching across systems and connects customers more quickly to relevant QIAGEN information

Expands QIAGEN’s digital ecosystem with AI-driven workflow support embedded directly into the customer experience

QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows

Wed, 20 May 2026 16:05:00 -0400

New AI-powered scientific platform available on www.qiagen.com connects experiment planning, product discovery and workflow support through a single conversational interface

Natural-language experience helps reduce time spent searching across systems and connects customers more quickly to relevant QIAGEN information

Expands QIAGEN’s digital ecosystem with AI-driven workflow support embedded directly into the customer experience

QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows

Wed, 20 May 2026 16:05:00 -0400

New AI-powered scientific platform available on www.qiagen.com connects experiment planning, product discovery and workflow support through a single conversational interface

Natural-language experience helps reduce time spent searching across systems and connects customers more quickly to relevant QIAGEN information

Expands QIAGEN’s digital ecosystem with AI-driven workflow support embedded directly into the customer experience

QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows

Wed, 20 May 2026 16:05:00 -0400

New AI-powered scientific platform available on www.qiagen.com connects experiment planning, product discovery and workflow support through a single conversational interface

Natural-language experience helps reduce time spent searching across systems and connects customers more quickly to relevant QIAGEN information

Expands QIAGEN’s digital ecosystem with AI-driven workflow support embedded directly into the customer experience

QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows

Wed, 20 May 2026 16:05:00 -0400

New AI-powered scientific platform available on www.qiagen.com connects experiment planning, product discovery and workflow support through a single conversational interface

Natural-language experience helps reduce time spent searching across systems and connects customers more quickly to relevant QIAGEN information

Expands QIAGEN’s digital ecosystem with AI-driven workflow support embedded directly into the customer experience

QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows

Wed, 20 May 2026 16:05:00 -0400

New AI-powered scientific platform available on www.qiagen.com connects experiment planning, product discovery and workflow support through a single conversational interface

Natural-language experience helps reduce time spent searching across systems and connects customers more quickly to relevant QIAGEN information

Expands QIAGEN’s digital ecosystem with AI-driven workflow support embedded directly into the customer experience

QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows

Wed, 20 May 2026 16:05:00 -0400

New AI-powered scientific platform available on www.qiagen.com connects experiment planning, product discovery and workflow support through a single conversational interface

Natural-language experience helps reduce time spent searching across systems and connects customers more quickly to relevant QIAGEN information

Expands QIAGEN’s digital ecosystem with AI-driven workflow support embedded directly into the customer experience

QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA

Tue, 19 May 2026 16:05:00 -0400

Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights’ curated biomedical knowledge bases
Goal to advance how disease mechanisms, therapeutic targets and biomarkers are identified
Graph-based AI approach designed to help researchers explore mechanisms, therapeutic targets and biomarkers with greater speed, context and confidence
Initial pilot programs available to select pharmaceutical and biotechnology partners, with broader availability in future stages following validation

VENLO, Netherlands & REDWOOD CITY, Calif.--(BUSINESS WIRE)-- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced at the 2026 BIO-IT World Conference & Expo in Boston that the QIAGEN Digital Insights bioinformatics business and

QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA

Tue, 19 May 2026 16:05:00 -0400

Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights’ curated biomedical knowledge bases
Goal to advance how disease mechanisms, therapeutic targets and biomarkers are identified
Graph-based AI approach designed to help researchers explore mechanisms, therapeutic targets and biomarkers with greater speed, context and confidence
Initial pilot programs available to select pharmaceutical and biotechnology partners, with broader availability in future stages following validation

QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA

Tue, 19 May 2026 16:05:00 -0400

Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights’ curated biomedical knowledge bases
Goal to advance how disease mechanisms, therapeutic targets and biomarkers are identified
Graph-based AI approach designed to help researchers explore mechanisms, therapeutic targets and biomarkers with greater speed, context and confidence
Initial pilot programs available to select pharmaceutical and biotechnology partners, with broader availability in future stages following validation